Symptomatic non-insulin-dependent diabetes mellitus during therapy with recombinant human growth hormone.
In a 12-year-old girl, hyperglycemia and an elevated glycohemoglobin concentration developed after therapy with growth hormone for familial short stature. Both clinical and biochemical abnormalities disappeared after therapy was discontinued. The insulin response to an oral glucose tolerance test was abnormal 3 months after discontinuation of growth hormone; 18 months later, it remained delayed but was normal quantitatively.
Botero
D
D
Department of Pediatrics, University of Massachusetts Medical School, Worcester 01655.
Danon
M
M
Brown
R S
RS
D001827:Body Height; D002648:Child; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D005951:Glucose Tolerance Test; D006130:Growth Disorders / Q000188:drug therapy* / Q000235:genetics; D013006:Growth Hormone / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D011994:Recombinant Proteins; D013006:Growth Hormone